Clinical trial
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic…
NCT00015951 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00015951 |
|---|---|
| Title | Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers |
| Official title | A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC #704865, IND # 7,921) Administered in Times Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Refractory and Relapsed Acute… |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | National Cancer Institute (NCI) NIH University of Maryland Greenebaum Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, cytarabine, mitoxantrone hydrochloride |
| Start date | Apr 1, 2001 |
| Primary completion | Apr 1, 2003 |
| Completion | Mar 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: